Tetra Pharm Technologies ApS: Financial statements 2025
CVR: 40738223
Source: annual report 2025, Danish Business Authority
01/01/2025 – 31/12/2025
Tetra Pharm Technologies ApS (CVR 40738223) has filed annual accounts for 2025. In 2025, the company reported a gross profit of DKK -17,669,007 and a net result of DKK -52,589,605 compared with DKK -55,213,708 the year before. Equity in the 2025 report amounted to DKK -25,844,292. The company had 47 employees in the financial year.
- Gross Profit
- DKK -17,669,007
- Profit/Loss
- DKK -52,589,605
- Equity
- DKK -25,844,292
- Total Assets
- DKK 22,569,526
- Employees
- 47
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2025 | - | -17.7M | -52.6M | -25.8M | 47 |
| 2024 | - | 1.5M | -55.2M | 26.7M | 37 |
| 2023 | - | 585K | -32.9M | 32.1M | 24 |
| 2022 | - | -510K | -7.8M | 79.9M | 15 |
| 2021 | - | 3.2M | 306K | 9.9M | 6 |
Official annual report
How creditworthy is Tetra Pharm Technologies ApS?
See the CDS score and get a full credit report with recommended credit limit and payment terms.
Read about the CDS scoreEvents in 2025
As of October 10, 2025, Breum Holding EST. 2016 ApS is registered as an owner of Tetra Pharm Technologies ApS with an ownership share of 20%.
As of October 10, 2025, BrainFrame ApS is registered as an owner of Tetra Pharm Technologies ApS with an ownership share of 20%.
Tetra Pharm Technologies ApS has published its annual report for 2024. Gross profit came to DKK 1,460,638, and the net result was DKK -55,213,708.
As of May 23, 2025, Søren Rose has left the board of directors of Tetra Pharm Technologies ApS.
As of April 1, 2025, Jesper Breum has joined the board of directors of Tetra Pharm Technologies ApS.
As of March 31, 2025, Jesper Breum has left the board of directors of Tetra Pharm Technologies ApS.
As of March 28, 2025, Nikolay Tretiyakov has left the board of directors of Tetra Pharm Technologies ApS.
About Tetra Pharm Technologies ApS
Tetra Pharm Technologies ApS is a Danish company of the type Anpartsselskab based in København S, founded in 2019. The company is registered under the industry Fremstilling af farmaceutiske præparater. The management consists of Rolf Sass Sørensen and Ulrich Wulff Norden Venge. The board consists of Søren Maarssø (chair), Claus Berner Nielsen, Jesper Breum and Rolf Sass Sørensen. The company's owners include RUMP INVEST ApS, Breum Holding EST. 2016 ApS and BrainFrame ApS. The company has 39 employees (2026). In 2025, the company reported a gross profit of DKK -17,669,007 and a net result of DKK -52,589,605 compared with DKK -55,213,708 the year before. Equity in the 2025 report amounted to DKK -25,844,292.